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CASE STUDY
Transtuzumab induced organizing 
pneumonia: a case report
Ajay Gupta1,2*, Louise Teo2, Philip Masel3, David Godbolt4 and Geoffrey Beadle5
Abstract 
Background: Patients with metastatic breast cancer often have pulmonary symptoms with varying aetiologies. Tran-
stuzumab is an extremely important drug used in the treatment of Her 2 neu over-expressing breast cancers. In this 
report we describe a case of organizing pneumonia associated with use of transtuzumab in metastatic breast cancer. 
Only three such cases have previously been reported.
Case description: A 43 year old lady with Her 2 neu 3+, estrogen and progesterone receptor positive, metastatic 
breast cancer was started on weekly transtuzumab and albumen bound paclitaxel. She was admitted with an episode 
of bilateral pneumonitis after her fourth dose of therapy. It was managed conservatively with antibiotics. Subse-
quently, single agent transtuzumab was administered resulting in an anaphylactoid reaction followed by worsening 
dyspnoea requiring hospitalization and oxygen support for 3 days.
Discussion and evaluation: The pneumonitis warranted further investigations including bronchoscopy which 
were performed. Bronchoscopic biopsy was consistent with a diagnosis of organizing pneumonia. Transtuzumab was 
stopped and she was started on steroids (dexamethasone). She improved remarkably and was discharged home on 
hormonal therapy, lapatinib and tapering doses of steroids.
Conclusion: Organizing pneumonia closely mimics infection or progressive disease and can be difficult to diagnose 
in the setting of malignancy. Correct diagnosis is of paramount importance since delay in treatment can result in 
significantly adverse patient outcomes.
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Background
Patients with metastatic breast cancer often have pulmo-
nary symptoms with varying aetiologies. Organizing pneu-
monia mimics infection or progressive malignancy and can 
be difficult to diagnose especially in the setting of malig-
nancy. Transtuzumab is a monoclonal antibody against 
the Her-2 neu epidermal growth factor receptor, used in 
the treatment of Her 2 neu over-expressing breast cancers. 
Only three cases of organising pneumonia, in association 
with transtuzumab therapy, have previously been described 
(Travis et  al. 2013; King and Mortenson 1992; Mokhtari 
et  al. 2002; Cook-Burns 2001; Vahid and Mehrotra 2006; 
Perez et  al. 2014; Pepels et  al. 2009; Romond et  al. 2005; 
Radzikowska et  al. 2003; Taus-García et  al. 2010; Grudny 
et al. 2004). We present the report of such a case.
Case presentation
A 43-year-old, premenopausal, lady, was evaluated at an 
outside hospital for complaints of a lump in her right 
breast of three months duration. She also had severe 
bone pains and numbness in her chin, since the last one 
month. She was diagnosed to have metastatic breast 
cancer. Biopsy was suggestive of high grade infiltrat-
ing duct carcinoma which was further characterised as 
being estrogen, progesterone receptor positive and Her 
2 neu 3+ by immunohistochemistry. Contrast Enhanced 
Computerised Tomography scans (CECT scans) of the 
chest and abdomen and Magnetic Resonance Imaging 
(MRI) of the brain, head and neck region revealed mul-
tiple lung, liver and bone metastases including the right 
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acromion as well as parameningeal and right mandibular 
bony infiltration which was consistent with mental nerve 
neuropathy.
She was given palliative radiation to the painful right 
acromial lesion. She was then started on chemotherapy 
with albumen bound paclitaxel 100  mg/m2 weekly and 
transtuzumab 4 mg/kg as loading dose followed by 2 mg/
kg weekly. Two to four hours following each dose of tran-
stuzumab, she would have episodes of high grade fever of 
up to 39  °C associated with mild chills, resolving spon-
taneously without intervention over the next 1–3  days. 
After the fourth dose, she developed bilateral pneumoni-
tis (non-neutropenic) for which she had to be admitted to 
hospital for treatment with intravenous antibiotics. The 
CECT scan of the chest revealed extensive bilateral patchy 
areas of air space disease with interstitial involvement. 
Two weeks later, she improved and was given another 
dose of transtuzumab and albumen bound paclitaxel and 
then discharged. A week after receipt of her last dose, she 
presented to our hospital emergency with complaints of 
respiratory distress and hypoxia. CECT Scan of the chest 
and abdomen revealed dense extensive right upper and 
left lower lobe para-mediastinal consolidation along with 
smaller, bilateral patches and air bronchograms consistent 
with a diagnosis of organizing pneumonia (Fig. 1a, b). Sep-
tal lines and interstitial opacities in the mid lower zones 
suggested lymphangitis. There was evidence of progres-
sive disease with multiple liver and bone metastases. The 
patient was started on oxygen, antibiotics, intravenous 
dexamethasone and supportive care. In view of progres-
sive disease, albumen bound paclitaxel was discontinued. 
Hormonal therapy comprising goserelin depot prepara-
tion 3.6  mg administered subcutaneously every 28  days 
and anastrazole orally 1 mg daily was commenced.
Four days later, single agent transtuzumab was admin-
istered, to which she developed an anaphylactoid reaction 
with symptoms of acute breathlessness and hypotension. 
This was managed successfully with steroids, antihista-
minics and intravenous fluids. The reaction resolved but 
her breathlessness did not and she in fact developed pro-
gressively worsening dyspnoea, with an oxygen saturation 
of 84% on room air, requiring supplemental oxygen, anti-
biotics and parenteral steroids. Her condition improved 
after 3 days of supportive care. Parenteral steroids were 
then stopped and oral dexamethasone 8 mg thrice daily 
was commenced. A bronchoscopy was conducted.
The biopsy revealed  patchy intra-alveolar haemor-
rhage and fibrin deposition with collections of intra-
alveolar foamy macrophages, patchy reactive type II 
pneumocyte hyperplasia and focal organizing pneumonia 
(Fig. 2a). There was also a localised interstitial infiltrate of 
polygonal cells forming tubular structures and a small ill-
defined sheet (Fig. 2b). Changes suggestive of lymphatic 
invasion were evident. The polygonal cells were positive 
for estrogen receptor and GATA 3 (Fig. 2c) and negative 
for TTF1,  consistent with metastatic breast carcinoma. 
There was no history of exposure to fumes and no micro-
biological or serological evidence of any pathogens or 
collagen-vascular disease.
Her symptoms resolved over the next two weeks and 
she was discharged home. The CECT scan of the chest 
done at discharge (Fig. 1c, d) revealed marked reduction 
in the organizing pneumonia and interstitial infiltrates. 
Lapatinib 1250  mg daily was added to her treatment 
regimen. Dexamethasone was slowly tapered off over the 
next 4 weeks. At last follow-up, 8 weeks post-discharge, 
she was doing well on therapy.
Organizing pneumonia or bronchiolitis obliterans 
organizing pneumonia (BOOP) is one of the major Idi-
opathic Interstitial Pneumonias (IIP) (Travis et al. 2013). 
Typical radiological features include multiple alveolar 
opacities, usually bilateral and peripheral, often migra-
tory, varying in size from a few centimeters to a whole 
lobe, with air bronchograms often present in consoli-
dated opacities: as in our case. The disease is pathologi-
cally defined by the presence of buds of granulation tissue 
formed by fibrin exudates, fibroblasts, myofibroblasts 
and loose connective tissue in distal air spaces (alveolar 
spaces and bronchiolar lumen), although lung structure 
is preserved. Treatment tends to be steroid-responsive, 
though scarring may persist (Travis et al. 2013; King and 
Mortenson 1992). In our case, organizing pneumonia 
was held to be secondary and differentials included infec-
tions, malignancy, transtuzumab, paclitaxel or prior radia-
tion. However the absence of any demonstrable pathogen 
and the occurrence of bilateral lesions outside the known 
extrathoracic radiation field precluded infections or radia-
tion as a cause. The strong temporal association of hyper-
sensitivity reactions with single agent transtuzumab and 
marked resolution of the disease process on stopping the 
drug, strongly suggests a role of transtuzumab in its aeti-
ology. A probable causative or contributory role of malig-
nancy in its aetiology, cannot be fully excluded.
Drug-induced infiltrative lung disease (DI-ILD) is the 
most common form of anti-neoplastic agent-induced 
respiratory disease. Its spectrum includes non-specific 
interstitial pneumonia, eosinophilic pneumonia, hyper-
sensitivity pneumonitis, pulmonary fibrosis, or organiz-
ing pneumonia (Travis et al. 2013; King and Mortenson 
1992).
The association of malignancy with BOOP is an infre-
quently described clinical entity and mimics various res-
piratory conditions. In the largest retrospective study 
describing this phenomenon, 43 patients with an under-
lying diagnosis of cancer were found on lung biopsy to 
have BOOP as an isolated entity. All patients had received 
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therapy including chemotherapy (71%) or radiother-
apy 9(21%), only 7 had surgery alone. Two patients who 
had received extra-thoracic radiation developed BOOP 
2–3 years after treatment, while others who received tho-
racic radiation developed BOOP ipsilateral to the radia-
tion port. One case of breast cancer was also reported. 
Patients with solid organ tumours were more likely to 
have nodular or mass like radiographic abnormalities 
(81%) rather than diffuse infiltrates (19%). The opposite 
pattern was observed in patients with hematologic malig-
nancies (22 vs. 67%). Most patients recovered on steroids 
or macrolides but the disease was fatal in 3 patients with 
haematological malignancies (Mokhtari et al. 2002).
Transtuzumab is reasonably safe to use and only about 
0.3% patients have serious reactions with features of ana-
phylaxis or bronchospasm, usually occurring within 2.5 h 
of drug administration (Cook-Burns 2001; Vahid and 
Mehrotra 2006).
Trastuzumab-associated pneumonitis is a rare, poten-
tially fatal side effect, presenting as hypoxemia, dyspnoea 
and respiratory failure. Common radiological findings are 
interstitial infiltrates with a ground-glass appearance and 
patchy foci of airspace consolidation. In the trial National 
Surgical Adjuvant Breast and Bowel Program (NSABP) 
B-31, of 2102 women enrolled, four patients in the trastu-
zumab group had interstitial pneumonitis, one of whom 
who died (Vahid and Mehrotra 2006; Perez et al. 2014). 
In the North Central Cancer Treatment Group (NCCTG) 
N9831 trial, of 1944 women, five patients in the trastu-
zumab group had grade 3+ pneumonitis or pulmonary 
infiltrates, one of whom who died (Perez et  al. 2014; 
Pepels et al. 2009; Romond et al. 2005).
Fig. 1 CECT of the Chest revealing. a Extensive right upper lobe consolidation, bronchocentric consolidation with air bronchogram, band like and 
peripheral consolidation and b the “reversed halo” sign of focal perilobular consolidation with central ground-glass opacities suggestive of organiz-
ing pneumonia. c, d CECT of the Chest before discharge revealing marked resolution of the organizing pneumonia after cessation of transtuzumab
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Only three cases of transtuzumab induced organizing 
pneumonitis have been described so far. One patient, 
49 years old, developed it 6 weeks after starting transtu-
zumab and this resolved three months after its cessation. 
Another patient, 60 years old, developed it after 11 cycles 
and this too resolved three months after drug cessation 
(Radzikowska et al. 2003; Taus-García et al. 2010; Grudny 
et al. 2004).
Pneumonitis rates of 4% have been described with 
albumen bound paclitaxel in combination with gemcit-
abine, especially in patients with pancreatic cancer. How-
ever none of these episodes were Grade 3 or higher and 
were not fatal (Von Hoff et al. 2013).
Paclitaxel is also known to cause pneumonitis with 
an estimated frequency of 0.7%, more so in combina-
tion with gemcitabine or irinotecan. Dyspnea, cough, 
hypoxemia, and pulmonary infiltrates usually develop 
1  week to 3  months into therapy. Severe pneumoni-
tis and pulmonary fibrosis resulting in death have been 
described but mild cases tend to resolve spontaneously 
(Khan et al. 1997).
Conclusions
Organizing pneumonias can occur in patients with meta-
static cancers. Patients undergoing treatments for can-
cer with either chemotherapy or targeted treatments 
may develop drug induced organizing pneumonitis as a 
rare adverse reaction. Clinical and radiological features 
closely mimic infection or progressive malignancy: thus a 
high index of suspicion is needed for diagnosis. Failure to 
diagnose may lead to delays in treatment and translate in 
deleterious patient outcomes to patients.
Fig. 2 H&E staining 200× photomicrographs showing a focal intra-alveolar fibrin deposition with patchy reactive type II pneumocyte hyperplasia 
and focal organising pneumonia; b focal infiltrate of polygonal cells forming tubular like structures; c Described infiltrate of polygonal cells positive 
for GATA3 consistent with metastatic breast carcinoma
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